Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

Selective ER Degrader

LY3484356

Selective ER Degrader

Gladden AB and Diehl JA1; Patel HK and Bihani T2; Tecalco-Cruz AC, et al3; Wardell SE, et al4

Target
Estrogen signaling plays an important role in organ development and growth. In certain cancers, abnormal estrogen signaling via the estrogen receptor is a key component of tumor growth.5 Disruption of estrogen signaling by selective estrogen receptor degraders (SERDs) is one of the treatment options for patients with estrogen-receptor-positive (ER+) cancers.
Molecule
LY3484356 is an orally available SERD that has demonstrated the inhibition of estrogen signaling and subsequent inhibition of cell proliferation in ER-expressing tumor models.
Clinical Development
LY3484356 is being investigated in clinical trials in patients with breast cancer or endometrial cancer.

References

  1. Gladden AB, Diehl JA. J Cell Biochem. 2005;96(5):906-913.
  2. Patel HK, Bihani T. Pharmacol Ther. 2018;186:1-24.
  3. Tecalco-Cruz AC, et al. Cell Signal. 2017;34:121-132.
  4. Wardell SE, et al. Clin Cancer Res. 2015;21(22):5121-5130.
  5. Lee HR, et al. Int J Mol Med. 2012;29:883-890.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

DISCOVER OTHER MOLECULES

IDH1 Inhibitor

Learn More

CDK4 & 6 Inhibitor

Learn More

VEGF Receptor-2 Antagonist

Learn More